{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "hmdb:HMDB06564",
      "entity_text" : "glucose",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:11949646",
      "entity_text" : "empagliflozin",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Review of CV outcome trials in this Perspective demonstrates that liraglutide, semaglutide, pioglitazone, and empagliflozin reduce macrovascular events by 14-26%, independent of their glucose lowering effect and improvement in traditional CV risk factors (XREF_FIG).",
  "reading_complete" : "2020-07-28T13:15:48Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T13:12:11Z",
  "trigger" : "reduce",
  "evidence" : [ "empagliflozin reduce macrovascular events by 14-26%, independent of their glucose" ],
  "pmc_id" : "5481984",
  "score" : 0
}